Author

Joseph Francis O'Donnell

OpenAlex ID: A5042373345

Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs).

2023 · Meredith McAdams, Shannon Swift, et al. · Journal of Clinical Oncology · 12

A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

2023 · Alan Haruo Bryce, Daniel D. Karp, et al. · Journal of Clinical Oncology · 4

Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).

2025 · Alan Haruo Bryce, Karim Fizazi, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 16

H-index: 2

I10-index: 1